Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. These insurers are often building barriers to access, like significant expense criteria and PA that restrict consumer opportunity. Analysts suggest t